SCHEMBL981735

SCHEMBL981735

COc1ccc(CC(=O)N2CCC(c3ccc4c(c3)OCO4)=N2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
RAB9A P51151 3/20 0.58
HPGD P15428 2/20 0.58
MCHR1 Q99705 1/20 0.52
TERT O14746 1/20 0.48
MEN1 O00255 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47
MAOB P27338 3/20 0.46
NPC1 O15118 1/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
EDNRB P24530 1/20 0.46
EDNRA P25101 1/20 0.46
MAPT P10636 1/20 0.45
AURKA O14965 1/20 0.45
CSNK1E P49674 1/20 0.45
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL979547 0.89 RAB9A (0.50) ALDH1A1SMN1; SMN2RAB9AHPGDMCHR1
SCHEMBL980150 0.87 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2RAB9AHPGDMAOB
SCHEMBL981460 0.86 USP2 (0.45) ALDH1A1SMN1; SMN2RAB9AHPGDTERT
SCHEMBL982358 0.86 ALOX15 (0.47) ALDH1A1SMN1; SMN2RAB9AHPGDMCHR1
SCHEMBL981326 0.84 MAOB (0.65) ALDH1A1SMN1; SMN2RAB9AHPGDMAOB
SCHEMBL980235 0.83 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2RAB9AHPGDMAOB
SCHEMBL980195 0.81 SMN1; SMN2 (0.68) ALDH1A1SMN1; SMN2RAB9AHPGDMEN1
SCHEMBL982366 0.81 SMN1; SMN2 (0.68) ALDH1A1SMN1; SMN2RAB9AHPGDMEN1
SCHEMBL979286 0.81 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2RAB9AHPGDMEN1
SCHEMBL984394 0.81 SMN1; SMN2 (0.70) ALDH1A1SMN1; SMN2RAB9AHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 ALDH1A1 399/4885SMN1; SMN2 4245/4885RAB9A 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.